Primary study of chemoradiotherapy combined with radioactive iodine-125 implantation for locally advanced non-small cell lung cancer
Yuan Peng1, Li Wenhui2, Yue Tianhua1, Yuan Lin3, Chen Bin4, Dai Zhenhuang2
1Department of Intervention,Jianhu Hospital Affiliated to Nantong University,Nantong 224700,China; 2Department of Intervention,Yancheng Hospital Affiliated to Southeast University,Nantong 224001,China; 3Department of Radiation Oncology,Jianhu Hospital Affiliated to Nantong University,Nantong 224700,China; 4Department of Radiation Oncology,Yancheng Hospital Affiliated to Southeast University,Nantong 224001,China
Objective To comparatively evaluate the clinical efficacy and adverse events of chemoradiotherapy combined with/without radioactive iodine-125(125-I) implantation for locally advanced non-small cell lung cancer. Methods With locally advanced non-small cell lung cancer admitted to Department of Radiotherapy of Jianhu County People's Hospital and Yancheng Third People's Hospital from March 2014 to March 2015 of 38 patients were enrolledand randomly divided into the observation (chemoradiotherapy+ radioactive 125-I implantation, n=20) and control groups (chemoradiotherapy, n=18). All patients underwent conventional three-dimensional conformal radiotherapy and TC chemotherapy. In the observation group, 125-I implantation was performed at 3 months after chemoradiotherapy. The short-term clinical efficacy,progression-free survival,overall survival and adverse events were statistically compared between two groups. Results The total effective rate in the observation group was 85%,significantly higher than 56% in the control group (P=0.046). Until May, 2018,the progression-free survival rates in the observation and control groups were 65% and 61%(P=0.457),the overall survival rates were 32% and 26%,and the median survival time was 22.8(95%CI:20.5-23.5) and 21.3(95%CI:15.9-26.0) months (P=0.633). The incidence rates of adverse events in the observation and control groups were 45% and 78%(P>0.05). Conclusions Concurrent chemoradiotherapy combined with radioactive 125-I implantation yields high short-term efficacy in the treatment of locally advanced non-small cell lung cancer. It can prolong the long-term survival to certain extent and yield a low incidence rate of severe adverse events,which deserves to be validated by large sample-size investigations.
Yuan Peng,Li Wenhui,Yue Tianhua et al. Primary study of chemoradiotherapy combined with radioactive iodine-125 implantation for locally advanced non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(8): 584-587.
[1] 王宝强,周陈华. 紫杉醇联合顺铂同步放化疗治疗局部进展期非小细胞肺癌的临床疗效及安全性评价[J]. 中国临床药理学杂志,2015,12(8):603-605. DOI:10.13699/j.cnki.1001-6821.2015.08.006.
Wang BQ,Zhou CH. Clinical efficacy and safety evaluation of paclitaxel combined with cisplatin synchronous radiotherapy and chemotherapy in the treatment of locally advanced non-small cell lung cancer[J]. Chin J Clin Pharmacol,2015,12(8):603-605. DOI:10.13699/j.cnki.1001-6821.2015.08.006.
[2] Huang Q,Jabbour SK,Xiao Z,et al. Dosimetric feasibility of 4DCT-ventilation imaging guided proton therapy for locally advanced non-small-cell lung cancer[J]. Radiat Oncol,2018,13(1):78. DOI:org/10.1186/s13014-018-1018-x.
[3] 沈文斌,祝淑钗,高红梅,等. 肿瘤体积和放疗剂量对局部晚期非小细胞肺癌预后的影响[J]. 中国肿瘤临床,2012,39(5):278-282. DOI:10.3969/j.issn.1000-8179.2012.05.009.
Shen WB,Zhu SC,Gao HM,et al. Effect of tumor volume and radiotherapy dose on prognosis of locally advanced non-small cell lung cancer[J]. Chin J Clin Oncol,2012,39(5):278-282. DOI:10.3969/j.issn.1000-8179.2012.05.009.
[4] Wong SL,Ricketts K,Royle G,et al. A methodology to extract outcomes from routine healthcare data for patients with locally advanced non-small cell lung cancer[J]. BMC Heal Serv Res,2018,18(1):278. DOI:org/10.1016/S0169-5002(16)30131-3.
[5] Nyg rdL,Vogelius IR,Rischer BM,et al. A competing risk model of first failure site after definitive chemoradiation therapy for locally advanced non-small cell lung cancer[J]. J Thora Oncol,2018,13(4):559-567. DOI:org/10.1016/j.jtho.2017.12.011.
[6] 陈智伟,廖美琳,陈玉蓉,等. WHO标准和RECIST标准评价肺癌化疗疗效的比较[C].中国临床肿瘤学教育专辑(2004),2004:30-32.
Chen ZW,Liao ML,Chen YR,et al. WHO standards and RECIST standards to evaluate the efficacy of chemotherapy for lung cancer[C]. China clinical oncology education album (2004),2004:30-32.
[7] Ni J,Yin ZM,Yuan SH,等. 妇科恶性肿瘤术后盆腔调强放疗与三维适形放疗的随机研究[J]. 中华妇产科杂志, 2017,52(3):168-174. DOI:10.3760/cma.j.issn.0529-567x.2017.03.006.
Ni J,Yin ZM,Yuan SH,et al. A randomized study of intensity-modulated radiation therapy versus three dimensional conformal radiation therapy for pelvic radiation in patients of post-operative treatment with gynecologic malignant tumor[J]. Chin J Obstet Gynecol,2017,52(3):168-174. DOI:10.3760/cma.j.issn.0529-567x.2017.03.006.
[8] 章辉. 肿瘤化疗药物的毒副反应及处理[C].杭州:浙江省药剂学术会议,2006.
Zhang H. Toxic side effects and treatment of tumor chemotherapy drugs[C]. Hangzhou:Zhejiang pharmaceutical academic conference,2006.
[9] 张真,张小涛,韩淑红,等. PET-CT定位局部晚期非小细胞肺癌IMRT同步化疗的疗效和预后分析[J]. 中国肿瘤临床,2013,9(15):930-933. DOI:10.3969/j.issn.1000-8179.2013.15.013.
Zhang Z,Zhang XD,Han SH,et al. Efficacy and prognosis of PET-CT localization of locally advanced non-small cell lung cancer IMRT synchronous chemotherapy[J]. Chin J Clin Oncol,2013,9(15):930-933. DOI:10.3969/j.issn.1000-8179.2013.15.013.
[10] 王岚,刘畅,巩传凤,等. 调强放疗联合紫杉醇及恩度治疗老年局部晚期非小细胞肺癌的临床疗效[J]. 中国老年学杂志,2014,12(24):6913-6915. DOI:10.3969/j.issn.1005-9202.2014.24.030.
Wang L,Liu C,Gong CF,et al. Clinical efficacy of intensity modulated radiotherapy combined with paclitaxel and kindness in the treatment of senile locally advanced non-small cell lung cancer[J]. Chin J Gerontol,2014,12(24):6913-6915. DOI:10.3969/j.issn.1005-9202.2014.24.030.
2019, Vol. 28 
